Cambridge startup inspires AI-led approach to cancer trials Business Weekly Technology News Business news

Cambridge Cancer Genomics is leveraging its AI platform in a new partnership designed to more accurately target tumours in precision clinical trials. It is working with Precision-Panc, a UK-wide network of over 20 hospitals that can offer such trials to patients with pancreatic cancer. The broad-based collaboration sets out to improve and standardise data analysis, distribution and sharing in platform these vital diagnostic programmes. Startup CCG.ai is building software for data-driven precision oncology and its technology forms the basis of the piloted standardisation infrastructure and will provide insights into Precision-Panc's large-scale, multi-centre, oncology trials. CCG.ai's platform – OncOS – automates the analysis of cancer DNA samples and matches suitable clinical trials based on the underlying molecular features of a tumour, simplifying and streamlining data sharing to accelerate translation into the clinic.